SIGMA-SYSTEMS
2.5.2017 11:02:08 CEST | Business Wire | Press release
Sigma Systems, a global leader in catalog-driven software, has appointed Catherine Michel as Chief Technology Officer (CTO).
Michel previously served as Chief Strategy Officer (CSO) on Sigma’s leadership team, and currently sits on the TM Forum Executive Committee, has been named as one of the most powerful people in the telecoms industry by Global Telecoms Business, and is a public advocate and mentor for women in telco and IT. As Sigma’s Chief Technology Officer, Catherine is responsible for the company's product portfolio and strategy.
“Catherine is a globally respected member of the IT and communications technology community, and we are very fortunate to have her on the Sigma team. She has an excellent track record of innovation within the software development arena and is a highly strategic thinker. Catherine has been vital in driving Sigma’s product portfolio forward, and will continue to do so in her new role in the coming months and years. Catherine is a key spokesperson for the company at events and technology forums across the globe,” said Tim Spencer, Sigma’s President and CEO.
Prior to her roles at Sigma, Michel was the founder and CTO of Tribold, where she was the principal architect of the company's products and solutions portfolio. Tribold was acquired by Sigma in 2013. Prior to co-founding Tribold, she was a senior executive in Accenture's Communications and High Tech practice, devising and delivering business strategy and large-scale B/OSS solutions globally.
“Sigma is on the cutting edge of delivering technology solutions that enable operators to truly transform into agile digital service providers,” observed Michel. “I continue to be excited about the position we’ve achieved in the market and the opportunities ahead of us.”
Catherine will be speaking at TM Forum Live! in Nice with Sigma customer Windstream. The joint presentation will outline how Windstream developed, governed and executed a widespread digital transformation program in parallel with a major acquisition and SDN deployment. As a key strategic partner, Sigma is supporting Windstream’s transition to an agile delivery organization with the adoption of catalog-driven Agile B/OSS. Sigma’s portfolio is designed to support CSPs like Windstream to embrace digital innovation and enable the rapid launch and fulfilment of new products and services without entirely dismantling existing legacy systems.
Presentation Details:
May 15th
, 11:15am
TM Forum
Live!
Palais des Congrès Acropolis, Nice, France
About Sigma Systems (
sigma-systems.com
or Twitter @SigmaSystems)
Sigma Systems is a global leader in
catalog-driven software solutions for communications, media, and
high-tech companies. It serves over 80 customers in 40 countries with
its award-winning products.
The company’s portfolio spans enterprise-wide Catalog, Configure Price Quote (CPQ), Order Management and Provisioning products, which can be deployed in the cloud or on-premise. Sigma utilizes an agile approach to implementing its B/OSS products for its customers.
Sigma has offices in North and South America, Europe and Asia, with technology and integration partners in over 100 countries.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170502005185/en/
Contact:
Sigma Systems
Noor Manji, 416-943-9696
Manager, Corporate
Communications
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom